246 related articles for article (PubMed ID: 16457972)
1. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Sugiyama I; Tsuruda T; Sonobe T
Int J Pharm; 2006 Apr; 312(1-2):83-9. PubMed ID: 16457972
[TBL] [Abstract][Full Text] [Related]
2. Effect of hybridized liposome by novel modification with some polyethyleneglycol-lipids.
Sugiyama I; Sonobe T; Sadzuka Y
Int J Pharm; 2009 May; 372(1-2):177-83. PubMed ID: 19429278
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel mixed polyethyleneglycol modified liposomes.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2007 Jan; 30(1):208-11. PubMed ID: 17202690
[TBL] [Abstract][Full Text] [Related]
4. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes].
Sadzuka Y; Tsuruda T; Sonobe T
Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286
[TBL] [Abstract][Full Text] [Related]
5. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome.
Sadzuka Y; Nakade A; Hirama R; Miyagishima A; Nozawa Y; Hirota S; Sonobe T
Int J Pharm; 2002 May; 238(1-2):171-80. PubMed ID: 11996821
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Sugiyama I; Sadzuka Y
Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): drug release behavior and stability in the presence of serum.
Han HD; Shin BC; Choi HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):110-6. PubMed ID: 16183268
[TBL] [Abstract][Full Text] [Related]
9. Correlation of fixed aqueous layer thickness around PEG-modified liposomes with in vivo efficacy of antitumor agent-containing liposomes.
Sugiyama I; Sadzuka Y
Curr Drug Discov Technol; 2011 Dec; 8(4):357-66. PubMed ID: 22034853
[TBL] [Abstract][Full Text] [Related]
10. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin.
Sadzuka Y; Nakade A; Tsuruda T; Sonobe T
J Control Release; 2003 Sep; 91(3):271-80. PubMed ID: 12932707
[TBL] [Abstract][Full Text] [Related]
11. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
12. Change in the character of liposomes as a drug carrier by modifying various polyethyleneglycol-lipids.
Sugiyama I; Sadzuka Y
Biol Pharm Bull; 2013; 36(6):900-6. PubMed ID: 23727913
[TBL] [Abstract][Full Text] [Related]
13. Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes.
Shimada K; Miyagishima A; Sadzuka Y; Nozawa Y; Mochizuki Y; Ohshima H; Hirota S
J Drug Target; 1995; 3(4):283-9. PubMed ID: 8821002
[TBL] [Abstract][Full Text] [Related]
14. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
15. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
16. The phototoxicity of photofrin was enhanced by PEGylated liposome in vitro.
Sadzuka Y; Tokutomi K; Iwasaki F; Sugiyama I; Hirano T; Konno H; Oku N; Sonobe T
Cancer Lett; 2006 Sep; 241(1):42-8. PubMed ID: 16303246
[TBL] [Abstract][Full Text] [Related]
17. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
18. [To Assess Drug Delivery System Nanocarrier at Industrial Production: Establishment of Liposomal Surface Using Physicochemical Properties].
Sadzuka Y
Yakugaku Zasshi; 2024; 144(1):61-69. PubMed ID: 38171797
[TBL] [Abstract][Full Text] [Related]
19. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
